Gilead Sciences, Inc. Expected to Post Q3 2022 Earnings of $1.59 Per Share (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) – Research analysts at Oppenheimer upped their Q3 2022 earnings per share (EPS) estimates for Gilead Sciences in a note issued to investors on Wednesday, August 3rd. Oppenheimer analyst H. Singh now expects that the biopharmaceutical company will earn $1.59 per share for the quarter, up from their prior estimate of $1.52. The consensus estimate for Gilead Sciences’ current full-year earnings is $6.58 per share. Oppenheimer also issued estimates for Gilead Sciences’ Q4 2022 earnings at $1.29 EPS, FY2022 earnings at $6.58 EPS, FY2023 earnings at $6.49 EPS, FY2024 earnings at $6.83 EPS, FY2025 earnings at $7.53 EPS and FY2026 earnings at $7.34 EPS.

A number of other brokerages have also recently weighed in on GILD. SVB Leerink started coverage on Gilead Sciences in a research report on Monday, May 23rd. They issued a “market perform” rating and a $68.00 price target on the stock. TheStreet cut Gilead Sciences from a “b-” rating to a “c+” rating in a research report on Friday, July 1st. BMO Capital Markets started coverage on Gilead Sciences in a research report on Tuesday, June 7th. They issued a “hold” rating and a $63.00 price target on the stock. StockNews.com cut Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Thursday. Finally, Morgan Stanley upped their price target on Gilead Sciences from $63.00 to $65.00 and gave the company an “equal weight” rating in a research report on Friday, July 15th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, Gilead Sciences has an average rating of “Hold” and a consensus target price of $72.07.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $61.09 on Thursday. The business has a fifty day simple moving average of $61.55 and a 200 day simple moving average of $61.93. Gilead Sciences has a one year low of $57.17 and a one year high of $74.12. The firm has a market capitalization of $76.63 billion, a price-to-earnings ratio of 18.63, a PEG ratio of 0.63 and a beta of 0.34. The company has a current ratio of 1.49, a quick ratio of 1.30 and a debt-to-equity ratio of 1.31.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 29th. Investors of record on Thursday, September 15th will be issued a $0.73 dividend. This represents a $2.92 annualized dividend and a yield of 4.78%. The ex-dividend date of this dividend is Wednesday, September 14th. Gilead Sciences’s dividend payout ratio is 89.02%.

Hedge Funds Weigh In On Gilead Sciences

Several hedge funds have recently added to or reduced their stakes in GILD. Joseph P. Lucia & Associates LLC bought a new position in Gilead Sciences in the first quarter valued at about $25,000. TFO TDC LLC bought a new position in Gilead Sciences in the first quarter valued at about $27,000. FSB Premier Wealth Management Inc. bought a new position in Gilead Sciences in the fourth quarter valued at about $28,000. Zullo Investment Group Inc. lifted its stake in Gilead Sciences by 1,969.6% in the first quarter. Zullo Investment Group Inc. now owns 476 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 453 shares during the period. Finally, Landmark Wealth Management LLC acquired a new position in Gilead Sciences in the first quarter valued at about $30,000. Institutional investors own 80.16% of the company’s stock.

About Gilead Sciences

(Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

See Also

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.